Is Opicapone marketed in capsule form?

Opicapone (Opicapone) is an oral prescription drug, mainly used together with levodopa (Levodopa) and carbidopa (Carbidopa) for patients with "non" attacks of Parkinson's disease (PD). It is mainly used for the adjuvant treatment of Parkinson's disease. It belongs to the catechol-O-methyltransferase (COMT) inhibitor drug class, which can prolong the action of levodopa in the body, thereby reducing the frequency and severity of movement disorders in patients with Parkinson's disease. It's not known whether Opicapone is safe and effective in children.

Opicapone is indeed available in capsule form and is marketed under the brand nameOngentys. Each capsule may contain 25 mg or 50 mg of opicapone, a peripheral, selective, and reversible inhibitor of COMT. Capsule dosage forms usually have convenient administration methods, good stability and better absorption properties, which help to improve the bioavailability of drugs. Patients can choose the capsule formulation of Opicapone for treatment according to the doctor's advice, ensuring that the correct dose and medication time are taken.

According to the doctor's prescription, it is generally recommended to take a daily dose of 50 mg of Opicapone once before going to bed, at least an hour before and after the combined drug with levodopa. Opicapone is well tolerated and usually does not cause serious adverse events, but common side effects such as disturbances of the nervous system (brain and spinal cord) may occur.

Before using Opicapone, patients should read the drug instructions carefully to understand the contraindications, precautions and possible adverse reactions, and follow the doctor's guidance for correct medication management.